Investigation into huge price increases for generics in the US

Generics/General | Posted 21/11/2014 post-comment0 Post your comment

Two US Congressmen have sent letters to 14 drug manufacturers, including several major Indian firms, requesting information about the escalating prices they have been charging for generics.

Pay for Delay DrugsMoneyGeneric V13F21

The 14 generics companies who have received letters include Indian pharma majors such as Sun Pharmaceutical Industries (Sun Pharma), Dr Reddy’s Laboratories, and Zydus Pharmaceuticals USA (a subsidiary of India-based Cadila Pharmaceuticals). US companies included in the investigation are Actavis, Heritage Pharmaceuticals, Lannett Company, Marathon Pharmaceuticals, Mylan, Par Pharmaceutical Companies, and West-Ward Pharmaceutical. Canada-based Apotex, Ireland-based Endo International, China-based Global Pharmaceuticals, and Israel-based Teva Pharmaceutical Industries have also received letters.

The action comes in response to recent reports of price hikes in generics. For example, a report by the American Society of Health-System Pharmacists found that half of all generics sold through retailers became more expensive during the 12 months July 2013–July 2014. In fact, the prices paid by pharmacies more than doubled for one out of 11 generics, and in the case of the antibiotic tetracycline and the blood pressure pill captopril exceeded 17,000%.

US Senator Bernie Sanders and US Congressman Elijah E Cummings point to ‘staggering price increases’ in the range of 390–8,200% across 10 products and have asked the 14 generics makers to submit detailed information.

‘It is unacceptable that Americans pay, by far, the highest prices in the world for prescription drugs. Generic drugs were meant to help make medications affordable for the millions of Americans who rely on prescriptions to manage their health needs. We’ve got to get to the bottom of these enormous price increases,’ Sanders said.

Related article
Another old drug to see huge price increase in US

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2014 Pro PharmaCommunications International. All Rights Reserved.

Source: Indian Business Standard, US Senate, WSJ

comment icon Comments (0)
Post your comment
Related content
FDA reaches 100 generic approvals
53 MD002445
Generics/General Posted 12/11/2021
New five-year medicines agreements in Australia
24-AA011041
Generics/General Posted 24/09/2021
Generics applications under review by EMA – July 2021
EMA logo 2 V13F14
Generics/General Posted 23/07/2021
Most viewed articles
About GaBI
Home/About GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010